Cargando…

Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report

RATIONALE: The potential efficacy of apatinib in patients with advanced triple-negative breast cancer (TNBC) has been observed in a previous phase II clinical study. However, there is no study to evaluate its efficacy and safety in TNBC patients with brain metastasis (BM). Here we report one case th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ting, Wang, Shan-Bing, Lei, Kai-Jian, Jiang, Mao-Qiong, Jia, Yu-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358397/ https://www.ncbi.nlm.nih.gov/pubmed/30681587 http://dx.doi.org/10.1097/MD.0000000000014182

Ejemplares similares

Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC
por: Ren, Yue, et al.
Publicado: (2021)

Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases
por: Xu, Jianping, et al.
Publicado: (2020)

Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review
por: Hu, Ting, et al.
Publicado: (2018)

The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases
por: Chen, Xuelian, et al.
Publicado: (2023)

Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report
por: Jin, Jun, et al.
Publicado: (2019)

Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases
por: Ying, Xiaofang, et al.
Publicado: (2020)

Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer
por: Jin, Jia, et al.
Publicado: (2018)

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
por: Hu, Xichun, et al.
Publicado: (2014)

Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial
por: Cao, Mengru, et al.
Publicado: (2023)

Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion
por: Zhao, Lingying, et al.
Publicado: (2022)

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
por: Lin, Haimin, et al.
Publicado: (2019)

Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study
por: Li, Yi-Hui, et al.
Publicado: (2018)

Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases: A single-center observational study
por: Zheng, Kai, et al.
Publicado: (2018)

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
por: Liu, Ying-ying, et al.
Publicado: (2019)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies
por: Li, Haosheng, et al.
Publicado: (2022)

Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
por: Li, Dou-Dou, et al.
Publicado: (2022)

A case report of apatinib in treating osteosarcoma with pulmonary metastases
por: Zhou, Yong, et al.
Publicado: (2017)

Ultrasound-Targeted Microbubble Destruction Enhances Inhibitory Effect of Apatinib on Angiogenesis in Triple Negative Breast Carcinoma Xenografts
por: Hong, Dengke, et al.
Publicado: (2021)

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
por: Liu, Jieqiong, et al.
Publicado: (2022)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
por: Yordanova, Mariya, et al.
Publicado: (2021)

THER-06. GENOMIC AND IMMUNE CHARACTERIZATION OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES
por: Vincent, Benjamin, et al.
Publicado: (2019)

Key Role of Hyaluronan Metabolism for the Development of Brain Metastases in Triple-Negative Breast Cancer
por: Hamester, Fabienne, et al.
Publicado: (2022)

Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study
por: Wang, Fen, et al.
Publicado: (2020)

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
por: Liu, Jieqiong, et al.
Publicado: (2020)

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
por: Zhang, Qingyuan, et al.
Publicado: (2022)

Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis
por: Huang, Xuchen, et al.
Publicado: (2022)

Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers
por: Bryan, Sarah, et al.
Publicado: (2021)

Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419
por: Routh, Eric D., et al.
Publicado: (2022)

Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer
por: Chen, Jianzhao, et al.
Publicado: (2021)

Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial
por: Yang, Ciqiu, et al.
Publicado: (2022)

Anaplastic lymphoma kinase-negative pulmonary inflammatory myofibroblastic tumor with multiple metastases and its treatment by Apatinib: A case report
por: Liu, Qiuxia, et al.
Publicado: (2019)

Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy
por: Wang, Xue, et al.
Publicado: (2022)

Exceptional Eight-year Response to Stereotactic Radiosurgery Monotherapy for Multiple Brain Metastases
por: Kalash, Ronny, et al.
Publicado: (2017)

Apatinib monotherapy for advanced non‐small cell lung cancer after the failure of chemotherapy or other targeted therapy
por: Liu, Zui, et al.
Publicado: (2018)

Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival
por: Tozbikian, Gary, et al.
Publicado: (2014)

Retracted: Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases
por: Contreras-Zárate, Maria J., et al.
Publicado: (2019)

Focal pyroptosis-related genes AIM2 and ZBP1 are prognostic markers for triple-negative breast cancer with brain metastases
por: Huang, Qian Fang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_klrubtqhcoi0q9rkcvu4j5il46